Meanwhile, Lilly gets in on the next-gen KRAS action.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.